Wikipedia

Mood stabilizer

A mood stabilizer is a psychiatric medication used to treat mood disorders characterized by intense and sustained mood shifts, such as bipolar disorder and the bipolar type of schizoaffective disorder.

A bottle of lithium capsules. Lithium is the prototypical mood stabilizer.

Uses

edit

Mood stabilizers are considered a cornerstone in the treatment of bipolar disorder, where they help prevent relapses into both manic and depressive episodes and maintain long-term mood stability. [1]

They are also prescribed for the bipolar type of schizoaffective disorder, and in some cases are used as adjuncts for treatment-resistant major depressive disorder. In addition, certain mood stabilizers have been shown to reduce impulsivity and aggression in selected psychiatric and neurological conditions. [2][3]

Evidence also suggests that lithium, in particular, reduces the risk of suicide in patients with mood disorders, making it a unique therapeutic option among mood stabilizers.[4]

Examples

edit

The term "mood stabilizer" does not describe a mechanism but an effect. More precise terminology based on pharmacology is used to further classify these agents. Drugs commonly classed as mood stabilizers include:

Mineral

edit
Lithium
Lithium is the "classic" mood stabilizer, the first to be approved by the US FDA, and still popular in treatment. Therapeutic drug monitoring is required to ensure lithium levels remain in the therapeutic range: 0.6 to 0.8 or 0.8–1.2 mEq/L (or millimolar). Signs and symptoms of toxicity include nausea, vomiting, diarrhea, and ataxia.[5] The most common side effects are lethargy and weight gain (up to 2 kilograms (4.4 lb)).[6] The less common side effects of using lithium are blurred vision, a slight tremble in the hands, and a feeling of being mildly ill (malaise). In general, these side effects occur in the first few weeks after commencing lithium treatment. These symptoms can often be improved by lowering the dose.[7] Long-term lithium therapy also carries risks such as hypothyroidism and chronic kidney disease, requiring periodic monitoring of thyroid and renal function.[8]
It is also one of the few mood stabilizers with proven anti-suicidal properties, making it unique among psychiatric medications.[9]

Anticonvulsants

edit

Anticonvulsants, also known as antiseizure medications, are agents originally developed for treating epilepsy and seizure disorders. In the 1970s, clinical trials demonstrated that certain anticonvulsants were effective in mood stabilization, subsequently, these medications were adopted in psychiatry for treating mood disorders. [10]

This class of medication is divided into first generation and second generation agents based on the time of their development, with the second generation agents having lesser adverse effects and better tolerability compared to the first generation.[11]

Valproate
Valproate is a first generation anticonvulsant agent. This drug is considered as the first line treatment for both acute mania and maintenance of bipolar disorder. [12] It primarily acts by inhibiting GABA transaminase and increasing GABAergic activity, thereby decreasing neuronal excitability. It can also inactivate sodium and calcium channels.[11]
This drug can be very irritating to the stomach, especially when taken as a free acid. Requires regular hepatic panels and full blood count monitoring. Common side effects include sleepiness, nausea, and dry mouth. More serious side effects include liver dysfunction, pancreatitis, and polycystic ovary syndrome.[13][14] Weight gain is possible.[15]
It is recommended that women of childbearing age should avoid using valproate due its teratogenic potential, including the increased risk of neural tube defects, even with folic acid supplementation. [16]

Carbamazepine

Carbamazepine is also a first generation anticonvulsant. It is considered second-line for bipolar disorder due to its side effects[17], including gastrointestinal symptoms, Stevens‐Johnson syndrome, toxic epidermal necrolysis, and weight gain. [16] It primarily acts by inhibiting sodium channels. [11]
Carbamazepine can rarely cause a dangerous decrease in neutrophils, a type of white blood cell, called agranulocytosis.[18] It interacts with many medications, including other mood stabilizers (e.g., lamotrigine) and antipsychotics (e.g., quetiapine).[18]
While using carbamazepine, the effectiveness of oral contraceptive is significantly decreased, and it also has
teratogenic potential. [16]
Lamotrigine (brand name Lamictal)
FDA-approved for bipolar disorder maintenance therapy, not for acute mood problems like acute depression or mania, including hypomania.[19] The usual target dose is 100–200 mg daily, titrated to by 25 mg increments every 2 weeks.[20] Lamotrigine can cause Stevens–Johnson syndrome, a very rare but potentially fatal skin condition.[19]

There is insufficient evidence to support the use of various other anticonvulsants, such as gabapentin and topiramate, as mood stabilizers.[21]

Antipsychotics

edit

Some atypical antipsychotics (aripiprazole, asenapine, cariprazine, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone) also have mood-stabilizing effects and are thus commonly prescribed even when psychotic symptoms are absent.[22]

Other

edit
Omega-3 fatty acids
It is also conjectured that omega-3 fatty acids may have mood-stabilizing effects.[23] Compared with placebo, omega-3 fatty acids appear better able to augment known mood stabilizers in reducing depressive—but perhaps not manic—symptoms of bipolar disorder; additional trials would be needed to establish the effects of omega-3 fatty acids alone.[24] Recent studies suggest that preparations with a higher ratio of eicosapentaenoic acid (EPA) to docosahexaenoic acid (DHA) -types of omega-3 fatty acids- are more effective in improving depressive symptoms, while effects on mania remain inconsistent.[25][26]
Levothyroxine
It is known that even subclinical hypothyroidism can blunt a patient's response to both mood stabilizers and antidepressants. Furthermore, preliminary research into the use of thyroid augmentation in patients with refractory and rapid-cycling bipolar disorder has been positive, showing a slowing in cycle frequency and reduction in symptoms. Most studies have been conducted on an open-label basis. One large, controlled study of a 300 mcg daily dose of levothyroxine (T4) found it superior to placebo in the setting of bipolar disorder. In general, studies have shown T4 to be well tolerated and to show effectiveness even in patients without overt hypothyroidism.[27] It is reported that supraphysiological doses of levothyroxine may be particularly beneficial in women with treatment-resistant bipolar depression, although long-term safety still needs further evaluation.[28] Hypothyroidism is common among patients with bipolar disorder regardless of the mood stabilizer used.[29]

Combination therapy

edit

In routine practice, monotherapy is often insufficiently effective for acute and/or maintenance therapy. Thus, most patients are placed on combination therapy.[30] Combination therapy (e.g., an atypical antipsychotic with lithium or valproate) has demonstrated better effectiveness over monotherapy in the control of manic episodes, as well as the prevention of relapse.[30] However, side effects are more frequent and discontinuation rates are higher due to adverse events with combination therapy than with monotherapy.[30]

Relationship to Antidepressants

edit

Most mood stabilizers are primarily antimanic agents, meaning that they are effective at treating mania and mood cycling and shifting, but are not effective at treating acute depression. The principal exceptions to that rule, because they treat both manic and depressive symptoms, are lamotrigine, lithium carbonate, olanzapine and quetiapine. There is a need for caution when treating bipolar patients with antidepressant medication due to the risks that they pose.[31][32][33]

See also: SSRI § Bipolar switch

Nevertheless, antidepressants are still often prescribed in addition to mood stabilizers during depressive phases. This brings some risks, however, as antidepressants can induce mania (increases risk by 34%),[34] psychosis (relative risk not reported),[35] cycle acceleration,[32] and other disturbing problems in people with bipolar disorder—in particular, when taken alone. The risk of antidepressant-induced mania when given to patients concomitantly on antimanic agents is not known for certain but may still exist.[36] SSRIs and bupropion appear to have lower chances of switching, while SNRIs and tricyclics are more likely to cause switching. A single large, population based study reports that the manic "switch" risk is not increased over regular mood stabilizer treatment when an antidepressant is combined with a mood stabilizer. When an antidepressant is used alone, the risk is about 3 times the regular value.[32] Gitlin (2018) notes that "the potential issue of worsening suicidality in adolescents and young adults treated with antidepressants [...] both controversial and infrequently seen."[32]

Equally critical is the question of whether adding antidepressant has any effect on bipolar depression. High-quality data is lacking in this field, and simply using different analytical approaches can lead to different conclusions. It's also possible that the effect depends on the mood stabilizer used: one study finds no effect when antidepressant is added to lithium or valporate, but some efficacy when it's added to atypical antipsychotics.[32]

Pharmacodynamics

edit

Pharmacodynamics refers to the study of the biochemical and cellular effects of medications, as well as their mechanisms of action.[37] As noted, "mood stabilizers" do not share a single way of working; the term simply indicates how these drugs are used in treatment. However, some research shows that Lithium, Valproate, and Carbamazepine may share a common mechanism of action, but not tricyclic antidepressants.[38] This mechanism includes the reduction of inositol, a compound involved in many pathways that lead to increased cell signaling in the brain.[39] When these pathways are inhibited or blocked, the mood stabilizing effect is accomplished.[38] Another possible target of several mood stabilizers is the arachidonic acid cascade.[40]

Lithium's exact mechanism of action remains unknown; it likely affects several sites within the neuron including the nucleus and the synapse. As mentioned, lithium is thought to cause inositol reduction. It does this by being an uncompetitive inhibitor to the enzymes inositol monophosphatase 1 and inositol polyphosphate 1-phosphatase.[41] Lithium is also known to inhibit the enzyme GSK-3B,[42] which helps regulate the circadian rhythm. If the circadian rhythm is disrupted, it may lead to key traits of Bipolar Disorder, like mood episodes.[43] Chronic use of lithium helps regulate gene transcription of brain-derived neurotrophic factor (BDNF).[44] This boosts neural plasticity; which may be key to lithium's therapeutic effects. Lithium's role in the human body isn't fully clear. However, its benefits likely connect to its impact on electrolytes like potassium, sodium, calcium, and magnesium.[45] Lithium is generally neuroprotective.[46]

Valproate, also known as Valproic Acid, is an anticonvulsant. It affects brain activity in several ways. Valproate's main effect is the indirect inhibition of the breakdown of GABA, which is an inhibitory neurotransmitter. It works by reducing the activity of enzymes that break down GABA. This includes GABA transaminase and succinate semialdehyde dehydrogenase.[47] It also decreases the expression of glutamate receptors; thus decreasing neuronal excitability. [47] In addition, valproate blocks sodium, potassium and calcium voltage-gated channels, and this reduces how often neurons fire. [48] [49] Research has since shown valproate to have several cellular effects. These include the inhibition of histone deacetylases and upregulation of LEF1. These mechanisms hint at possible uses in cancer therapy.[50][51] It is also neuroprotective.[46]

Carbamazepine is another anticonvulsant that functions mainly as a sodium channel blocker.[52] Voltage-gated sodium channels are found on the cell membrane of neurons and help create action potentials.[53] Carbamazepine keeps these channels inactivated, which stops continuous action potential firing.[54] The liver breaks down carbamazepine through the liver enzyme CYP3A4. Many drugs can change how CYP3A4 works. They can either boost or reduce its activity. This is why carbamazepine needs careful monitoring when other medications are used with it, with a possible need for dosage adjustment.[54]

Lamotrigine lowers excitatory nerve signaling in the central nervous system by lowering glutamate release.[55] [56] In addition, it increases inhibitory nerve signaling by boosting GABA release. [41][55] Recent studies suggest the lamotrigine is relatively safe during pregnancy, but does need close monitoring by a specialist. This is important because researchers have linked it to neonatal malformations, such as oral clefts.[57]

See also: Atypical antipsychotic § Pharmacodynamics

See also

edit

Categories

edit
Mood stabilizers
Drug classes defined by psychological effects
Drugs by psychological effects
Psychoactive drugs

References

edit
  1. ^ Stahl, Stephen M. (2021-07-29). Stahl's Essential Psychopharmacology. Cambridge University Press. doi:10.1017/9781108975292. ISBN 978-1-108-97529-2.
  2. ^ Miura, Tomofumi; Noma, Hisashi; Furukawa, Toshi A; Mitsuyasu, Hiroshi; Tanaka, Shiro; Stockton, Sarah; Salanti, Georgia; Motomura, Keisuke; Shimano-Katsuki, Satomi; Leucht, Stefan; Cipriani, Andrea; Geddes, John R; Kanba, Shigenobu (October 2014). "Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis". The Lancet Psychiatry. 1 (5): 351–359. doi:10.1016/S2215-0366(14)70314-1. PMID 26360999.
  3. ^ Kishi, Taro; Ikuta, Toshikazu; Matsuda, Yuki; Sakuma, Kenji; Okuya, Makoto; Mishima, Kazuo; Iwata, Nakao (2020-11-11). "Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials". Molecular Psychiatry. 26 (8): 4146–4157. doi:10.1038/s41380-020-00946-6. ISSN 1359-4184. PMC 8550938. PMID 33177610.
  4. ^ Cipriani, A.; Hawton, K.; Stockton, S.; Geddes, J. R. (2013-06-27). "Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis". BMJ. 346 (jun27 4): f3646. doi:10.1136/bmj.f3646. ISSN 1756-1833. PMID 23814104.
  5. ^ Marmol, F. (2008). "Lithium: Bipolar disorder and neurodegenerative diseases Possible cellular mechanisms of the therapeutic effects of lithium". Progress in Neuro-Psychopharmacology and Biological Psychiatry. 32 (8): 1761–1771. doi:10.1016/j.pnpbp.2008.08.012. PMID 18789369. S2CID 25861243.
  6. ^ Malhi GS, Tanious M, Bargh D, Das P, Berk M (2013). "Safe and effective use of lithium". Australian Prescriber. 36: 18–21. doi:10.18773/austprescr.2013.008.
  7. ^ Kozier, B et al. (2008). Fundamentals Of Nursing: Concepts, Process, and Practice. London: Pearson Education. p. 189.
  8. ^ Gitlin, Michael (December 2016). "Lithium side effects and toxicity: prevalence and management strategies". International Journal of Bipolar Disorders. 4 (1) 27. doi:10.1186/s40345-016-0068-y. ISSN 2194-7511. PMC 5164879. PMID 27900734.
  9. ^ Stahl, Stephen M. (2021-07-29). Stahl's Essential Psychopharmacology. Cambridge University Press. doi:10.1017/9781108975292. ISBN 978-1-108-97529-2.
  10. ^ Rybakowski, Janusz K. (2023-04-29). "Mood Stabilizers of First and Second Generation". Brain Sciences. 13 (5): 741. doi:10.3390/brainsci13050741. ISSN 2076-3425. PMC 10216063. PMID 37239213.
  11. ^ a b c Hakami, Tahir (September 2021). "Neuropharmacology of Antiseizure Drugs". Neuropsychopharmacology Reports. 41 (3): 336–351. doi:10.1002/npr2.12196. ISSN 2574-173X. PMC 8411307. PMID 34296824.
  12. ^ Crapanzano, Calogero; Casolaro, Ilaria; Amendola, Chiara; Damiani, Stefano (2022-08-31). "Lithium and Valproate in Bipolar Disorder: From International Evidence-based Guidelines to Clinical Predictors". Clinical Psychopharmacology and Neuroscience. 20 (3): 403–414. doi:10.9758/cpn.2022.20.3.403. ISSN 1738-1088. PMC 9329114. PMID 35879025.
  13. ^ "Depakote 500mg Tablets". electronic Medicine Compendium. Dataphram Communications Limited. Retrieved 28 September 2016.
  14. ^ "Depakote- divalproex sodium tablet, delayed release". Archived from the original on 5 March 2016. Retrieved 10 November 2015.
  15. ^ Chukwu J, Delanty N, Webb D, Cavalleri GL (January 2014). "Weight change, genetics and antiepileptic drugs". Expert Review of Clinical Pharmacology. 7 (1): 43–51. doi:10.1586/17512433.2014.857599. PMID 24308788. S2CID 33444886.
  16. ^ a b c Yatham, Lakshmi N; Kennedy, Sidney H; Parikh, Sagar V; Schaffer, Ayal; Bond, David J; Frey, Benicio N; Sharma, Verinder; Goldstein, Benjamin I; Rej, Soham; Beaulieu, Serge; Alda, Martin; MacQueen, Glenda; Milev, Roumen V; Ravindran, Arun; O'Donovan, Claire (March 2018). "Canadian Network for Mood and Anxiety Treatments ( CANMAT ) and International Society for Bipolar Disorders ( ISBD ) 2018 guidelines for the management of patients with bipolar disorder". Bipolar Disorders. 20 (2): 97–170. doi:10.1111/bdi.12609. ISSN 1398-5647. PMC 5947163. PMID 29536616.
  17. ^ Nevitt SJ, Marson AG, Weston J, Tudur Smith C (August 2018). "Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review". The Cochrane Database of Systematic Reviews. 2018 (8): CD001769. doi:10.1002/14651858.CD001769.pub4. PMC 6513104. PMID 30091458.
  18. ^ a b "EQUETRO(carbamazepine) Package Insert" (PDF). Validus Pharmaceuticals LLC. Archived from the original (PDF) on February 17, 2017. Retrieved 10 July 2020.
  19. ^ a b "Lamictal – FDA Prescribing Information".
  20. ^ Healy D. 2005 Psychiatric Drugs explained 4th ed. Churchill Liviingstone: London p.110
  21. ^ Terence A. Ketter (3 May 2007). Advances in Treatment of Bipolar Disorder. American Psychiatric Pub. p. 42. ISBN 978-1-58562-666-3.
  22. ^ Bowden CL (2005). "Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder". J Clin Psychiatry. 66. Suppl 3: 12–9. PMID 15762830.
  23. ^ Mirnikjoo B, Brown SE, Kim HF, Marangell LB, Sweatt JD, Weeber EJ (April 2001). "Protein kinase inhibition by omega-3 fatty acids". J. Biol. Chem. 276 (14): 10888–96. doi:10.1074/jbc.M008150200. PMID 11152679.
  24. ^ Gao, K.; Calabrese, J. R. (2005). "Newer treatment studies for bipolar depression". Bipolar Disorders. 7 (s5): 13–23. doi:10.1111/j.1399-5618.2005.00250.x. PMID 16225556.
  25. ^ Kraguljac, Nina V.; Montori, Victor M.; Pavuluri, Mani; Chai, High S.; Wilson, Brian S.; Unal, Sencan S. (2009). "Efficacy of omega-3 fatty acids in mood disorders - a systematic review and metaanalysis". Psychopharmacology Bulletin. 42 (3): 39–54. ISSN 0048-5764. PMID 19752840.
  26. ^ Grosso, Giuseppe; Pajak, Andrzej; Marventano, Stefano; Castellano, Sabrina; Galvano, Fabio; Bucolo, Claudio; Drago, Filippo; Caraci, Filippo (2014-05-07). "Role of Omega-3 Fatty Acids in the Treatment of Depressive Disorders: A Comprehensive Meta-Analysis of Randomized Clinical Trials". PLOS ONE. 9 (5): e96905. Bibcode:2014PLoSO...996905G. doi:10.1371/journal.pone.0096905. ISSN 1932-6203. PMC 4013121. PMID 24805797.
  27. ^ AMA Chakrabarti S. Thyroid Functions and Bipolar Affective Disorder. Journal of Thyroid Research. 2011;2011:306367. doi:10.4061/2011/306367. MLA Chakrabarti, Subho. "Thyroid Functions and Bipolar Affective Disorder". Journal of Thyroid Research 2011 (2011): 306367. PMC. Web. 19 May 2017. APA Chakrabarti, S. (2011). Thyroid Functions and Bipolar Affective Disorder. Journal of Thyroid Research, 2011, 306367. http://doi.org/10.4061/2011/306367
  28. ^ Seshadri, Ashok; Sundaresh, Vishnu; Prokop, Larry J.; Singh, Balwinder (2022-11-14). "Thyroid Hormone Augmentation for Bipolar Disorder: A Systematic Review". Brain Sciences. 12 (11): 1540. doi:10.3390/brainsci12111540. ISSN 2076-3425. PMC 9688441. PMID 36421864.
  29. ^ Lambert CG, Mazurie AJ, Lauve NR, Hurwitz NG, Young SS, Obenchain RL, Hengartner NW, Perkins DJ, Tohen M, Kerner B (May 2016). "Hypothyroidism risk compared among nine common bipolar disorder therapies in a large US cohort". Bipolar Disorders. 18 (3): 247–260. doi:10.1111/bdi.12391. PMC 5089566. PMID 27226264.
  30. ^ a b c Geoffroy, P. A.; Etain, B.; Henry, C.; Bellivier, F. (2012). "Combination Therapy for Manic Phases: A Critical Review of a Common Practice". CNS Neuroscience & Therapeutics. 18 (12): 957–964. doi:10.1111/cns.12017. PMC 6493634. PMID 23095277.
  31. ^ Chris Aiken: Antidepressants in Bipolar II Disorder, May 14, 2019. In: psychiatrictimes.com
  32. ^ a b c d e Gitlin MJ (December 2018). "Antidepressants in bipolar depression: an enduring controversy". International Journal of Bipolar Disorders. 6 (1) 25. doi:10.1186/s40345-018-0133-9. PMC 6269438. PMID 30506151.
  33. ^ Viktorin A, Lichtenstein P, Thase ME, Larsson H, Lundholm C, Magnusson PK, Landén M (October 2014). "The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer". The American Journal of Psychiatry. 171 (10): 1067–1073. doi:10.1176/appi.ajp.2014.13111501. hdl:10616/42159. PMID 24935197. S2CID 25152608.
  34. ^ Patel, Rashmi (2015). "Do antidepressants increase the risk of mania and bipolar disorder in people with depression? A retrospective electronic case register cohort study". BMJ Open. 5 (12): e008341. doi:10.1136/bmjopen-2015-008341. PMC 4679886. PMID 26667012.
  35. ^ Preda, A; MacLean, RW; Mazure, CM; Bowers MB, Jr (January 2001). "Antidepressant-associated mania and psychosis resulting in psychiatric admissions". The Journal of Clinical Psychiatry. 62 (1): 30–3. doi:10.4088/jcp.v62n0107. PMID 11235925.
  36. ^ Amit BH, Weizman A. Antidepressant Treatment for Acute Bipolar Depression: An Update. Depression Research and Treatment [Internet]. 2012 [cited 2013 Jul 18];2012:1–10. Available from: http://www.hindawi.com/journals/drt/2012/684725/
  37. ^ "Pharmacodynamics: Molecular Mechanisms of Drug Action". McGraw Hill Medical. Retrieved 2025-08-25.
  38. ^ a b Lubrich, Beate; van Calker, Dietrich (October 1999). "Inhibition of the High Affinity Myo-Inositol Transport System: A Common Mechanism of Action of Antibipolar Drugs?". Neuropsychopharmacology. 21 (4): 519–529. doi:10.1016/S0893-133X(99)00037-8. ISSN 1740-634X. PMID 10481836.
  39. ^ Concerto, Carmen; Chiarenza, Cecilia; Di Francesco, Antonio; Natale, Antimo; Privitera, Ivan; Rodolico, Alessandro; Trovato, Antonio; Aguglia, Andrea; Fisicaro, Francesco; Pennisi, Manuela; Bella, Rita; Petralia, Antonino; Signorelli, Maria Salvina; Lanza, Giuseppe (2023-02-20). "Neurobiology and Applications of Inositol in Psychiatry: A Narrative Review". Current Issues in Molecular Biology. 45 (2): 1762–1778. doi:10.3390/cimb45020113. ISSN 1467-3045. PMC 9955821. PMID 36826058.
  40. ^ Rao JS, Lee HJ, Rapoport SI, Bazinet RP (June 2008). "Mode of action of mood stabilizers: is the arachidonic acid cascade a common target?". Mol. Psychiatry. 13 (6): 585–96. doi:10.1038/mp.2008.31. PMID 18347600. S2CID 21273538.
  41. ^ a b Nath, Mala; Gupta, Vikas (2025), "Mood Stabilizers", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 32310601, retrieved 2025-08-25
  42. ^ Rohr, Kayla E.; McCarthy, Michael J. (2022-08-24). "The impact of lithium on circadian rhythms and implications for bipolar disorder pharmacotherapy". Neuroscience Letters. 786 136772. doi:10.1016/j.neulet.2022.136772. ISSN 1872-7972. PMC 11801369. PMID 35798199.
  43. ^ McCarthy, Michael J.; Gottlieb, John F.; Gonzalez, Robert; McClung, Colleen A.; Alloy, Lauren B.; Cain, Sean; Dulcis, Davide; Etain, Bruno; Frey, Benicio N.; Garbazza, Corrado; Ketchesin, Kyle D.; Landgraf, Dominic; Lee, Heon-Jeong; Marie-Claire, Cynthia; Nusslock, Robin (May 2022). "Neurobiological and behavioral mechanisms of circadian rhythm disruption in bipolar disorder: A critical multi-disciplinary literature review and agenda for future research from the ISBD task force on chronobiology". Bipolar Disorders. 24 (3): 232–263. doi:10.1111/bdi.13165. ISSN 1399-5618. PMC 9149148. PMID 34850507.
  44. ^ Deliyannides, Deborah A.; Graff, Jamie A.; Niño, Izael; Lee, Seonjoo; Husain, Mustafa M.; Forester, Brent P.; Crocco, Elizabeth; Vahia, Ipsit V.; Devanand, Davangere P. (September 2023). "Effects of lithium on serum Brain-Derived Neurotrophic Factor in Alzheimer's patients with agitation". International Journal of Geriatric Psychiatry. 38 (9): e6002. doi:10.1002/gps.6002. ISSN 1099-1166. PMID 37732619.
  45. ^ Raber, Jack H. "Lithium carbonate." The Gale Encyclopedia of Mental Disorders, edited by Madeline Harris and Ellen Thackerey, vol. 1, Gale, 2003, pp. 571-573. Gale eBooks, link.gale.com/apps/doc/CX3405700220/GVRL?u=tamp44898&sid=GVRL&xid=9ef84e18. Accessed 20 Jan. 2021.
  46. ^ a b Quiroz JA, Machado-Vieira R, Zarate CA, Manji HK (2010). "Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects". Neuropsychobiology. 62 (1): 50–60. doi:10.1159/000314310. PMC 2889681. PMID 20453535.
  47. ^ a b Mishra, Manish Kumar; Kukal, Samiksha; Paul, Priyanka Rani; Bora, Shivangi; Singh, Anju; Kukreti, Shrikant; Saso, Luciano; Muthusamy, Karthikeyan; Hasija, Yasha; Kukreti, Ritushree (2021-12-24). "Insights into Structural Modifications of Valproic Acid and Their Pharmacological Profile". Molecules (Basel, Switzerland). 27 (1): 104. doi:10.3390/molecules27010104. ISSN 1420-3049. PMC 8746633. PMID 35011339.
  48. ^ Ghodke-Puranik Y, Thorn CF, Lamba JK, Leeder JS, Song W, Birnbaum AK, Altman RB, Klein TE (April 2013). "Valproic acid pathway: pharmacokinetics and pharmacodynamics". Pharmacogenetics and Genomics. 23 (4): 236–241. doi:10.1097/FPC.0b013e32835ea0b2. PMC 3696515. PMID 23407051.
  49. ^ Van den Berg, R. J.; Kok, P.; Voskuyl, R. A. (January 1993). "Valproate and sodium currents in cultured hippocampal neurons". Experimental Brain Research. 93 (2): 279–287. doi:10.1007/BF00228395. ISSN 0014-4819. PMID 8387930.
  50. ^ Santos R, Linker SB, Stern S, Mendes AP, Shokhirev MN, Erikson G, Randolph-Moore L, Racha V, Kim Y, Kelsoe JR, Bang AG, Alda M, Marchetto MC, Gage FH (June 2021). "Deficient LEF1 expression is associated with lithium resistance and hyperexcitability in neurons derived from bipolar disorder patients". Molecular Psychiatry. 26 (6): 2440–2456. doi:10.1038/s41380-020-00981-3. PMC 9129103. PMID 33398088.
  51. ^ Gottlicher, M. (2001-12-17). "Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells". The EMBO Journal. 20 (24): 6969–6978. doi:10.1093/emboj/20.24.6969. PMC 125788. PMID 11742974.
  52. ^ Rogawski MA, Löscher W, Rho JM (May 2016). "Mechanisms of Action of Antiseizure Drugs and the Ketogenic Diet". Cold Spring Harbor Perspectives in Medicine. 6 (5): a022780. doi:10.1101/cshperspect.a022780. PMC 4852797. PMID 26801895.
  53. ^ Pal, Rohit; Kumar, Bhupinder; Akhtar, Md Jawaid; Chawla, Pooja A. (October 2021). "Voltage gated sodium channel inhibitors as anticonvulsant drugs: A systematic review on recent developments and structure activity relationship studies". Bioorganic Chemistry. 115 105230. doi:10.1016/j.bioorg.2021.105230. ISSN 1090-2120. PMID 34416507.
  54. ^ a b Dean, Laura (2012), Pratt, Victoria M.; Scott, Stuart A.; Pirmohamed, Munir; Esquivel, Bernard (eds.), "Carbamazepine Therapy and HLA Genotype", Medical Genetics Summaries, Bethesda (MD): National Center for Biotechnology Information (US), PMID 28520367, retrieved 2025-08-25
  55. ^ a b Cunningham, M. O.; Jones, R. S. (2000-08-23). "The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro". Neuropharmacology. 39 (11): 2139–2146. doi:10.1016/s0028-3908(00)00051-4. ISSN 0028-3908. PMID 10963757.
  56. ^ "Prescribing Information for LAMICTAL (lamotrigine)" (PDF). FDA. Archived from the original (PDF) on 12 January 2020. Retrieved 12 January 2020.
  57. ^ Kaplan, Yusuf Cem; Demir, Omer (2021). "Use of Phenytoin, Phenobarbital Carbamazepine, Levetiracetam Lamotrigine and Valproate in Pregnancy and Breastfeeding: Risk of Major Malformations, Dose-dependency, Monotherapy vs Polytherapy, Pharmacokinetics and Clinical Implications". Current Neuropharmacology. 19 (11): 1805–1824. doi:10.2174/1570159X19666210211150856. ISSN 1875-6190. PMC 9185784. PMID 33573557.
edit
Retrieved from "https://en.wikipedia.org/w/index.php?title=Mood_stabilizer&oldid=1308078733"